McGuire J J, Graber M, Licato N, Vincenz C, Coward J K, Nimec Z, Galivan J
Grace Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, New York 14263.
Cancer Res. 1989 Aug 15;49(16):4517-25.
We previously reported (J. Galivan et al., Proc. Natl. Acad. Sci. USA, 82: 2598-2602, 1985) the synthesis and characterization of DL-erythro,threo-gamma-fluoromethotrexate (FMTX). The individual diastereomers, DL-erythro-FMTX (eFMTX) and DL-threo-FMTX (tFMTX), and their radiolabeled counterparts have now been prepared and characterized. Transport of eFMTX (Km = 9.3 microM; Vmax = 7.5 pmol/min/10(7) cells) was similar to that of methotrexate (MTX: Km = 6.6-9.9 microM; Vmax = 11.4-14.2 pmol/min/10(7) cells), while tFMTX (Km = 65.1 microM; Vmax = 8.4 pmol/min/10(7) cells) was transported less efficiently. Both isomers were able to saturate intracellular dihydrofolate reductase and accumulate further as unbound intracellular drug. Based on competition experiments and studies with MTX transport-defective cell lines, both isomers utilized the reduced folate/MTX transport system. Efflux half-times for the isomers were similar to those of MTX. Each isomer was equivalent to MTX in its ability to inhibit dihydrofolate reductase activity and bind to intracellular dihydrofolate reductase when the intracellular drug concentration was limiting. Both isomers had drastically diminished capacity to be metabolized to poly(gamma-glutamyl) metabolites by isolated folylpolyglutamate synthetase and in whole cells; tFMTX was metabolized to a slightly lesser extent than eFMTX. Using the CCRF-CEM human leukemia and H35 rat hepatoma cell lines, the growth-inhibitory effects of eFMTX were almost the same as those of MTX during continuous exposure, while tFMTX was slightly less potent. This difference in growth-inhibitory potency of the two isomers correlated with their ability to inhibit de novo thymidylate synthesis in the H35 cell line. These results indicate that both diastereomers of FMTX are similar in their properties to MTX, except that both are incapable of being readily converted to polyglutamate derivatives. As a result of these properties, both isomers could be used under appropriate conditions in comparative studies with MTX to define the roles of MTX polyglutamates.
我们之前报道过(J. 加利万等人,《美国国家科学院院刊》,82: 2598 - 2602, 1985)DL - 赤藓糖型、苏阿糖型 - γ - 氟甲氨蝶呤(FMTX)的合成与表征。现在已经制备并表征了各个非对映异构体,即DL - 赤藓糖型FMTX(eFMTX)和DL - 苏阿糖型FMTX(tFMTX),以及它们的放射性标记对应物。eFMTX的转运(Km = 9.3微摩尔;Vmax = 7.5皮摩尔/分钟/10⁷个细胞)与甲氨蝶呤(MTX:Km = 6.6 - 9.9微摩尔;Vmax = 11.4 - 14.2皮摩尔/分钟/10⁷个细胞)相似,而tFMTX(Km = 65.1微摩尔;Vmax = 8.4皮摩尔/分钟/10⁷个细胞)的转运效率较低。两种异构体都能够使细胞内二氢叶酸还原酶饱和,并作为未结合的细胞内药物进一步积累。基于竞争实验和对MTX转运缺陷细胞系的研究,两种异构体都利用还原型叶酸/MTX转运系统。异构体的外排半衰期与MTX相似。当细胞内药物浓度有限时,每种异构体在抑制二氢叶酸还原酶活性和与细胞内二氢叶酸还原酶结合的能力方面与MTX相当。两种异构体被分离的叶酰聚谷氨酸合成酶和在全细胞中代谢为聚(γ - 谷氨酰)代谢物的能力都大幅降低;tFMTX的代谢程度略低于eFMTX。使用CCRF - CEM人白血病细胞系和H35大鼠肝癌细胞系,在持续暴露期间,eFMTX的生长抑制作用与MTX几乎相同,而tFMTX的效力略低。这两种异构体在生长抑制效力上的差异与其抑制H35细胞系中胸苷酸从头合成的能力相关。这些结果表明,FMTX的两种非对映异构体在性质上与MTX相似,只是两者都不能轻易转化为聚谷氨酸衍生物。由于这些性质,在与MTX的比较研究中,在适当条件下两种异构体都可用于确定MTX聚谷氨酸的作用。